NCT05476081 (READAPT) is a clinical trial of Aspirin in Ischemic Stroke, sponsored by University of L'Aquila.

Who is sponsoring NCT05476081?

NCT05476081 is sponsored by University of L'Aquila.

What drugs are being tested in NCT05476081?

Interventions in NCT05476081: Aspirin, Clopidogrel, Ticagrelor.

What condition does NCT05476081 study?

NCT05476081 studies Ischemic Stroke, TIA.

Is NCT05476081 still recruiting?

NCT05476081 is currently completed. Last updated 5 December 2024.

Last reviewed 2024-12-05 · How we verify

NCT05476081: READAPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA

Completed Last updated 5 December 2024

What this trial tests

trial testing Aspirin in Ischemic Stroke in 2,239 participants. Completed in 3 May 2023.

Timeline

3 February 2021

Primary endpoint
3 February 2023

3 May 2023

Quick facts

Lead sponsor	University of L'Aquila
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,239
Start date	3 February 2021
Primary completion	3 February 2023
Estimated completion	3 May 2023
Sites	127 locations across Italy

Drugs / interventions tested

Aspirin — full drug profile →
Clopidogrel (clopidogrel) — full drug profile →
Ticagrelor (ticagrelor) — full drug profile →

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →
TIA — all drugs for TIA →

Sponsor

University of L'Aquila

Who can join

18 and older, any sex, with Ischemic Stroke or TIA. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The REAl-life study on short-term Dual Antiplatelet treatment in Patients with ischemic stroke or Transient ischemic attack (READAPT) is an observational, multicenter, prospective study involving Italian centers. The study aims at evaluating effectiveness and safety of short-term (21-90 days) dual antiplatelet treatment (DAPT) in secondary prevention of mild-to-moderate ischemic stroke or high-risk TIA.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Divergence Between Clinical Trial Evidence and Actual Practice in Use of Dual Antiplatelet Therapy After Transient Ischemic Attack and Minor Stroke.
De Matteis E, De Santis F, Ornello R, Censori B, et al · · 2023 · cited 29× · PMID 36951052 · DOI 10.1161/strokeaha.122.041660
Combining Intravenous Thrombolysis and Dual Antiplatelet Treatment in Patients With Minor Ischemic Stroke: A Propensity Matched Analysis of the READAPT Study Cohort.
Ornello R, Foschi M, De Santis F, Romoli M, et al · · 2024 · cited 12× · PMID 39119964 · DOI 10.1161/jaha.124.036275
Beyond RCTs: Short-term dual antiplatelet therapy in secondary prevention of ischemic stroke and transient ischemic attack.
De Matteis E, Ornello R, De Santis F, Foschi M, et al · · 2024 · cited 9× · PMID 38869034 · DOI 10.1177/23969873241255250
Real-World Dual Antiplatelet Therapy Use Exceeds Randomized Trials Boundaries With Possible Safety Issues in Patients With Large Artery Atherosclerosis-Insights From the READAPT Study.
De Matteis E, De Santis F, Foschi M, Romoli M, et al · · 2025 · cited 2× · PMID 40265654 · DOI 10.1111/ene.70163
Exploring Sex Differences in Outcomes of Dual Antiplatelet Therapy for Patients With Noncardioembolic Mild-to-Moderate Ischemic Stroke or High-Risk Transient Ischemic Attack: A Propensity-Matched Analysis of the READAPT Study Cohort.
Foschi M, D'Anna L, De Matteis E, De Santis F, et al · · 2025 · cited 2× · PMID 39648888 · DOI 10.1161/strokeaha.124.049210
Defining short-term outcomes of minor ischemic stroke due to small artery occlusion in the era of dual antiplatelet treatment: A READAPT study sub-analysis.
Foschi M, De Matteis E, De Santis F, Romoli M, et al · · 2024 · cited 1× · PMID 39244893 · DOI 10.1016/j.jns.2024.123211
Characteristics and causes of recurrent ischemic events in minor ischemic stroke and TIA in the READAPT study.
De Santis F, Foschi M, Romoli M, Tassinari T, et al · · 2025 · PMID 40773777 · DOI 10.1016/j.jns.2025.123641
Real-world outcomes following dual antiplatelet therapy in mild-to-moderate ischemic stroke with anterior versus posterior circulation infarct: a READAPT study propensity matched analysis.
De Santis F, Ornello R, De Matteis E, D'Anna L, et al · · 2025 · PMID 40661752 · DOI 10.1177/17562864251351100

Verify or expand the search:

Other trials of Aspirin

Trials testing the same drug.

NCT07525635 — Aspirin Dosing in Pregnancy · EARLY_PHASE1 · not yet recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting
NCT07373756 — Randomized Controlled Study to Compare Efficacy of Aspirin 75mg and 150mg In the Prevention of Preeclampsia In High Risk · Phase 4 · not yet recruiting
NCT07180472 — Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol · Phase 4 · not yet recruiting
NCT06638151 — Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime) · Phase 2 · recruiting

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other University of L'Aquila trials

Trials by the same sponsor.

NCT06525987 — Telecoached Exercise Intervention for Connectivity Enhancement in Small Vessel Disease (TELECONNECT-SVD) · NA · recruiting
NCT06823466 — Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants · recruiting
NCT05816213 — Point-of-care Low-field MRI in Acute Stroke · not yet recruiting
NCT06958874 — Adjunctive Effect of Erythritol on Pocket Closure Rates · NA · recruiting
NCT06790459 — Effects of the Ultra-low Frequencies TENS on the Arousal Circuits · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05476081 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of L'Aquila
Last refreshed: 5 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05476081.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing